查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988347

同種異體細胞療法市場：2026-2032年全球市場預測（依產品類型、生產技術、適應症、細胞來源和最終用戶分類）

Allogeneic Cell Therapy Market by Product Type, Manufacturing Technology, Indication, Cell Source, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，同種異體細胞療法市場價值將達到 26.4 億美元，到 2026 年將成長至 30.2 億美元，到 2032 年將達到 67.9 億美元，複合年成長率為 14.44%。

主要市場統計數據
基準年 2025 26.4億美元
預計年份：2026年 30.2億美元
預測年份 2032 67.9億美元
複合年成長率 (%) 14.44%

對當前同種異體細胞療法趨勢的策略性展望，重點在於商業化準備、監管合規性和生產挑戰。

本執行摘要首先明確闡述了同種異體細胞療法的當前發展趨勢，並將該技術置於再生醫學和免疫療法更廣泛的發展脈絡中。同種異體細胞療法有望實現即時供應、產品品質穩定，並有望突破自體療法在臨床供應方面的局限性，從而改變研發者、生產商和支付方的決策標準。因此，相關人員正將投資重點從一次性個體生產轉向可擴展的生產平台和標準化管理策略。

生物製程技術、免疫工程和經營模式的融合發展如何重塑同種異體細胞療法的發展路徑和投資重點。

在異體細胞治療領域，技術進步、監管預期變化和經營模式演進共同推動變革。生產技術的進步，例如一次性生物反應器的成熟、精密的微載體系統和3D培養平台，提高了產量、改善了細胞質量，並實現了更可預測的規模化生產。這些技術變革降低了技術風險，加速了從實驗室生產到大量生產的過渡，並最終吸引了更多投資進入後期臨床專案。

預測新關稅措施對美國細胞治療生態系統的供應鏈韌性、資本規劃和監管合規性的累積影響。

美國在2025年實施的累積關稅可能透過多種機制對同種異體細胞療法的整個價值鏈產生影響。首先，對進口試劑、一次性組件和專用設備徵收關稅將增加依賴全球供應商的製造商的接收成本，從而改變研發商和契約製造的成本結構預期。為因應此變化，各機構可能會加快在地化供應、認證國內供應商或垂直整合關鍵上游工程投入的步伐，以降低貿易政策變化所帶來的風險。

以細分市場主導的洞察，將最終用戶角色、製造平台選擇、適應症優先順序、細胞來源和產品模式與策略發展路徑連結起來。

基於細分觀點，我們可以清楚地了解整個異體細胞治療價值鏈中科學、運作和商業性機會的集中位置。對終端使用者的分析表明，合約研究組織（CRO）是早期和後期研發階段的重要合作夥伴，提供專業的臨床實驗物流和流程轉移能力。另一方面，醫院和專科診所則作為關鍵的交付中心，需要與臨床工作流程和低溫運輸物流進行整合。研究機構仍然是轉化創新和生物標記發現的重要來源，為下游開發平臺提供支援。

區域趨勢和戰略挑戰正在影響美洲、歐洲、中東和非洲以及亞太地區的臨床策略、製造地和市場進入。

區域趨勢為在美洲、歐洲、中東和非洲以及亞太地區營運的相關人員帶來了不同的策略挑戰。在美洲，臨床活動高度集中，生產基礎設施投入龐大，這不僅支持了藥物的快速上市，也加劇了對熟練人才和專業設施的競爭。因此，在該地區營運的公司越來越重視擴充性的模組化生產系統和戰略夥伴關係關係，以加速實用化向臨床試驗的過渡。

決定細胞療法開發中競爭地位和業務永續營運的企業策略、夥伴關係和生產能力。

每家公司的策略都展現了它們在異體細胞治療生態系統中應對競爭與合作的獨特方式。主要企業正集中資源將差異化科學轉化為臨床優勢，同時建構或鞏固後期臨床試驗和商業化所需的生產能力。契約製造組織 (CMO) 和專業技術供應商發揮著至關重要的作用，它們提供可擴展的平台和監管方面的專業知識，使規模小規模的研發公司能夠在無需巨額資本投入的情況下推進業務發展。

為高階主管提供實用建議，以協調轉化科學、生產規模化、供應鏈韌性和支付方合作，從而推動商業化成功。

產業領導者應採取一系列切實可行的步驟，使科學目標與營運可行性和商業性價值一致。首先，在專案設計的早期階段優先考慮整合製程開發，同時最佳化細胞產品特性和可擴展的生產能力，從而避免後期開發階段代價高昂的重新設計。儘早協調轉化科學、程式工程和監管策略，可以縮短臨床試驗時間，並增強監理申報的效力。

採用混合研究途徑，結合文獻整合、專家訪談、技術檢驗和案例研究檢驗，以支持實務見解。

本分析採用混合方法，整合質性和量性訊息，旨在確保研究的嚴謹性和有效性。我們收集了最新的科學文獻、同行評審的轉化研究、監管指導文件、臨床試驗註冊數據以及公開的企業資訊披露，以確定技術、臨床開發和政策方面的基準趨勢。這些資訊來源提供了必要的技術和監管背景，有助於解讀基因編輯、細胞工程和製造技術的最新進展。

總結技術成熟度、業務永續營運和監管一致性如何決定哪些同種異體細胞療法計畫能夠取得持續的臨床和商業性影響。

總之，異體細胞療法領域正處於一個轉折點，技術成熟度、供應鏈策略和監管調整在此交匯，決定哪些計畫能夠取得持續的臨床和商業性成功。雖然現成產品有可能擴大患者群體並實現更有效率的給藥模式，但要真正發揮這種潛力，需要在科學設計、生產規模化和與支付方的合作方面進行精心協調。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 同種異體細胞療法市場：依產品類型分類

  • CAR-T療法
    • 基因改造
    • 沒有基因改造
  • 樹突細胞療法
    • 未成熟樹突狀細胞
    • 成熟樹突狀細胞
  • NK細胞療法
    • 基因改造
    • 未修改
  • 幹細胞療法
    • 造血系統
    • 間質

第9章 依製造技術分類的同種異體細胞療法市場

  • 2D培養系統
    • 分層燒瓶
    • 滾珠瓶
  • 3D球狀體培養
    • 使用鷹架
    • 沒有鷹架
  • 生物反應器系統
    • 多用途
    • 一次使用
  • 基於微載體的系統
    • 固定台
    • 攪拌罐

第10章：同種異體細胞療法市場：依適應症分類

  • 自體免疫疾病
    • 狼瘡
    • 多發性硬化症
    • 類風濕性關節炎
  • 心血管疾病
    • 心肌梗塞
    • 周邊動脈疾病
    • 中風
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 神經系統疾病
    • 阿茲海默症
    • 帕金森氏症
    • 脊髓損傷
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌

第11章 依細胞來源分類的同種異體細胞療法市場

  • 脂肪組織
  • 骨髓
  • 周邊血
  • 臍帶

第12章 同種異體細胞療法市場：依最終用戶分類

  • 合約研究機構
  • 醫院
  • 研究機構
  • 專科診所

第13章 同種異體細胞療法市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 同種異體細胞療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 同種異體細胞療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國異體細胞療法市場

第17章：中國異體細胞治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abeona Therapeutics Inc.
  • AlloSource
  • Anterogen.Co., Ltd.
  • Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • Athersys Inc.
  • Biorestorative Therapies Inc.
  • Biosolution Co., Ltd.
  • Bloodworks Northwest
  • Brainstorm Cell Limited
  • Caribou Biosciences
  • Fate Therapeutics
  • Gamida Cell
  • Hope Biosciences
  • JCR Pharmaceuticals Co., Ltd.
  • Mallinckrodt Pharmaceuticals
  • MEDIPOST Co., Ltd.
  • Mesoblast Ltd.
  • NuVasive Inc. by Globus Medical
  • RTI Surgical
  • Smith+Nephew PLC
  • Stempeutics Research Pvt. Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Tego Science Inc.
  • ViaCyte Inc. by Vertex Pharmaceuticals
Product Code: MRR-CA100284D019

The Allogeneic Cell Therapy Market was valued at USD 2.64 billion in 2025 and is projected to grow to USD 3.02 billion in 2026, with a CAGR of 14.44%, reaching USD 6.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.64 billion
Estimated Year [2026] USD 3.02 billion
Forecast Year [2032] USD 6.79 billion
CAGR (%) 14.44%

A strategic orientation to the current allogeneic cell therapy landscape that highlights commercialization readiness, regulatory alignment, and manufacturing imperatives

This executive summary opens with a clear orientation to the current allogeneic cell therapy landscape, situating the technology within the broader evolution of regenerative medicine and immunotherapy. Allogeneic approaches promise off-the-shelf availability, consistent product quality, and the potential to decouple clinical supply from autologous constraints, which changes the calculus for developers, manufacturers, and payers. As a result, stakeholders are shifting investments from one-off individualized production toward scalable manufacturing platforms and standardized control strategies.

In parallel, clinical development is moving beyond proof-of-concept into more complex trials that evaluate durability, safety across diverse patient populations, and real-world deliverability. Regulatory pathways are adapting, with agencies emphasizing robust comparability, potency assays, and supply chain traceability. Consequently, development teams must integrate translational science, process engineering, and regulatory strategy earlier in product design. This introduction frames the subsequent sections by highlighting the intersection of technology maturation, commercialization readiness, and the operational imperatives that determine which programs will progress from clinical promise to clinical practice.

How convergent advances in bioprocess technologies, immune engineering, and commercial models are reshaping development pathways and investment priorities in allogeneic cell therapy

The allogeneic cell therapy arena is experiencing transformative shifts driven by converging technological advances, evolving regulatory expectations, and shifting commercial models. Advances in manufacturing technology, including the maturation of single-use bioreactors, refined microcarrier systems, and three-dimensional culture platforms, are enabling higher yields, improved cell quality, and more predictable scalability. These technological changes reduce technical risk and accelerate the transition from bench to batch, which in turn attracts broader investment into late-stage clinical programs.

Concurrently, gene editing and immune engineering techniques are expanding the therapeutic scope by enabling universal donor constructs, alleviating host-versus-graft reactions, and improving persistence in vivo. These biological innovations are reshaping clinical development strategies and creating new regulatory questions around genetic modification, long-term follow-up, and assay standardization. As these techniques become more standardized, they drive a secondary wave of process innovation focused on integrating genetic manipulation into closed, GMP-compliant production flows.

Commercial models are also shifting. Payers and providers increasingly evaluate total cost of care and prefer therapies that can be delivered reliably at scale. This expectation places a premium on reproducible manufacturing, supply chain resilience, and demonstrable long-term benefits. As a result, partnerships between developers, contract research organizations, and manufacturing technology suppliers are becoming more strategic and long-term in nature, emphasizing shared platform investments and co-development of analytic methods. Taken together, these shifts compress timelines from discovery to commercialization for programs that align scientific innovation with scalable manufacturing and comprehensive regulatory strategies.

Projected cumulative impacts of new tariff measures on supply chain resilience, capital planning, and regulatory compliance within the United States cell therapy ecosystem

The introduction of cumulative United States tariffs in 2025 has the potential to reverberate across the allogeneic cell therapy value chain through several distinct mechanisms. First, tariffs on imported reagents, single-use components, and specialized equipment will increase landed costs for manufacturers that rely on global suppliers, thereby altering cost-structure assumptions for both developers and contract manufacturers. In response, organizations may accelerate efforts to localize supply, qualify domestic suppliers, or vertically integrate critical upstream inputs to reduce exposure to trade policy volatility.

Second, increased import costs can lengthen lead times and complicate inventory strategies for clinical and commercial supply. Developers running multi-site clinical programs may find logistics and cold-chain requirements more complex, prompting tighter coordination between clinical sites and manufacturing centers. This could encourage regionalization of supply chains, where production closer to patient populations reduces cross-border movement and mitigates tariff exposure, but it may also create disparities in access if regional manufacturing capacity is uneven.

Third, tariffs can influence capital allocation decisions. When imported capital equipment becomes more expensive, companies may delay or downsize planned investments in advanced bioreactor systems or automation. Conversely, they may prioritize modular, lower-capex solutions or seek leasing and vendor finance models to preserve capital for clinical development. This shift can slow the adoption of higher-throughput platforms in the short term while stimulating innovation in cost-effective manufacturing solutions.

Fourth, trade barriers tend to catalyze strategic realignments among suppliers and service providers. International suppliers may establish local production or distribution arms to retain market access, while domestic manufacturers could expand capacity to meet rising demand. Strategic partnerships, co-manufacturing agreements, and licensing arrangements may proliferate as firms seek to hedge tariff risk and maintain supply continuity.

Lastly, tariffs have implications for regulatory and compliance efforts. The need to qualify alternative suppliers and adapt validated processes to different component specifications increases the regulatory burden and operational complexity. Manufacturers will need to document comparability studies and potentially update regulatory filings, which can extend timelines and divert resources from other development priorities. Overall, the cumulative effect of tariffs in 2025 encourages a reappraisal of supply chain architecture, capital planning, and regulatory contingency strategies across the sector.

Segment-driven insights that map end-user roles, manufacturing platform choices, indication priorities, cell sources, and product modalities to strategic development pathways

A segmentation-driven view clarifies where scientific, operational, and commercial opportunities cluster across the allogeneic cell therapy value chain. When examining end users, Contract Research Organizations act as essential partners for early and late-stage development, providing specialized trial logistics and process transfer capabilities, whereas hospitals and specialty clinics function as primary delivery points that require integration with clinical workflows and cold-chain logistics. Research institutes remain critical sources of translational innovation and biomarker discovery that feed downstream development pipelines.

Manufacturing technology choices shape both product attributes and cost dynamics. Two-dimensional culture systems, historically used for early development, remain relevant for specific workflows but must evolve to meet scale demands through layered flasks and roller bottle formats. Three-dimensional spheroid culture approaches, whether scaffold-based or scaffold-free, are gaining traction for applications where native-like microenvironments enhance potency. Bioreactor systems, transitioning between multi-use and single-use configurations, are central to achieving closed-system processing and reducing contamination risk. Microcarrier based systems, including fixed bed and stirred tank variants, provide flexible routes to increase cell density while preserving phenotype, yet each technology requires bespoke analytics and downstream processing adaptations.

Indication segmentation highlights how therapeutic focus influences product design and development strategy. Autoimmune disorders such as lupus, multiple sclerosis, and rheumatoid arthritis demand durable immunomodulation with favorable safety margins. Cardiovascular indications like myocardial infarction, peripheral artery disease, and stroke prioritize tissue repair and functional recovery, which often requires delivery strategies that ensure cell retention and engraftment. Infectious disease applications, divided between bacterial and viral infections, necessitate rapid deployability and robust safety profiling. Neurological targets including Alzheimer's, Parkinson's, and spinal cord injury confront delivery barriers and the need for long-term durability, while oncology applications for hematological malignancies and solid tumors impose stringent efficacy thresholds and complex combination strategies.

Cell source and product type further influence manufacturing and regulatory strategy. Sources such as adipose tissue, bone marrow, peripheral blood, and umbilical cord each present unique harvest logistics, cell yields, and donor variability that affect upstream processing and donor screening. Product types including CAR-T constructs, dendritic cell therapies, NK cell therapies, and diverse stem cell approaches demand tailored genetic engineering, activation, and expansion workflows. Subcategories-such as gene edited versus non-gene edited CAR-T, immature versus mature dendritic cell preparations, engineered versus unmodified NK cells, and hematopoietic versus mesenchymal stem cell therapies-introduce additional analytical and comparability requirements. In practice, the most promising programs align indication biology with an optimized cell source and manufacturing platform that together address clinical need while minimizing process complexity.

Regional dynamics and strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape clinical strategy, manufacturing footprint, and market access

Regional dynamics create differentiated imperatives for stakeholders operating across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas exhibit concentrated clinical activity and substantial investment into manufacturing infrastructure, which supports rapid translation but also heightens competition for skilled talent and specialized facility capacity. Consequently, firms operating here often emphasize scalable, modular manufacturing systems and strategic partnerships to accelerate time to clinic.

Within Europe, Middle East & Africa, regulatory frameworks and market access policies vary across jurisdictions, shaping multi-country clinical strategies and commercial launch sequencing. Harmonization efforts and collaborative networks foster cross-border clinical programs, but developers must navigate diverse reimbursement models and national regulatory nuances. This region typically encourages strong center-of-excellence models that concentrate complex procedures at specialized institutions.

The Asia-Pacific region combines rapid clinical expansion with growing manufacturing capabilities and an appetite for public-private collaboration. Local investment in cell therapy research and domestic supplier ecosystems is increasing, creating opportunities to optimize cost structures and localize production. However, developers must account for heterogeneous regulatory maturity and varying standards for clinical trial design and post-market surveillance. Across all regions, cross-border collaboration and manufacturing footprint decisions will determine program resilience, patient access, and long-term sustainability.

How corporate strategies, partnerships, and manufacturing capabilities define competitive positioning and operational resilience in cell therapy development

Company strategies reveal distinct approaches to competing and collaborating within the allogeneic cell therapy ecosystem. Leading developers concentrate resources on translating differentiating science into clinical advantage while building or securing access to the manufacturing capacity required for late-stage trials and commercialization. Contract manufacturing organizations and specialized technology suppliers play a pivotal role by offering scalable platforms and regulatory expertise that enable smaller developers to advance without large capital expenditures.

Strategic partnerships, licensing agreements, and selective vertical integration are common responses to the challenge of delivering consistent product quality at scale. Firms that invest early in robust analytical development and potency assays reduce downstream comparability risk and accelerate regulatory interactions. Moreover, companies that diversify supplier bases and qualify alternative sources for critical raw materials demonstrate greater resilience to supply disruptions.

Competitive positioning also depends on how firms manage intellectual property, gene-editing platforms, and cell engineering know-how. Organizations that cultivate strong manufacturing knowledge transfer processes and invest in workforce training produce more reliable technology transfers and faster scale-up. Finally, corporate strategies increasingly reflect commercial considerations such as payer engagement, evidence generation for real-world outcomes, and the development of service-oriented offerings that bundle therapy supply with training and site support to facilitate adoption.

Practical recommendations for executives to align translational science, manufacturing scale-up, supply chain resilience, and payer engagement to drive commercialization success

Industry leaders should pursue a set of actionable measures that align scientific ambition with operational feasibility and commercial viability. First, prioritize integrated process development that co-optimizes cell product attributes and scalable manufacturing early in program design to avoid costly redesigns later in development. Early alignment between translational science, process engineering, and regulatory strategy reduces time to clinic and strengthens regulatory submissions.

Second, diversify supplier relationships for critical consumables and components while qualifying domestic alternatives where feasible to mitigate tariff and geopolitical risks. Securing multi-sourced supply chains and building inventory strategies tied to clinical milestones will protect trial continuity and commercial launch readiness. Third, invest in robust analytical platforms and potency assays that demonstrate mechanism of action and clinical relevance. Strong analytical evidence supports both regulatory interactions and payer discussions by connecting manufacturing control to clinical outcomes.

Fourth, consider flexible manufacturing models that combine internal capacity with strategic use of contract manufacturing organizations. This hybrid approach balances control over critical processes with the ability to scale rapidly when clinical or commercial demand materializes. Fifth, engage payers and health systems early to define value frameworks, real-world evidence requirements, and delivery pathways. Proactive engagement reduces reimbursement uncertainty and informs clinical trial endpoints that matter to stakeholders.

Finally, cultivate talent through targeted hiring and training programs focused on cell therapy manufacturing, quality systems, and regulatory affairs. Workforce readiness remains a bottleneck; investing in capability development will accelerate commercialization and improve operational quality. Together, these actions create a resilient, scalable pathway from laboratory innovation to sustainable patient access.

A mixed-method research approach combining literature synthesis, expert interviews, technology validation, and case study triangulation to underpin actionable insights

This analysis synthesizes qualitative and quantitative inputs using a mixed-method approach designed to ensure rigor and relevance. We compiled contemporary scientific literature, peer-reviewed translational studies, regulatory guidance documents, clinical trial registries, and publicly available corporate disclosures to establish baseline trends in technology, clinical development, and policy. These sources provided the technical and regulatory context necessary to interpret recent advances in gene editing, cell engineering, and manufacturing modalities.

We complemented documentary research with structured interviews of domain experts spanning developers, contract manufacturers, clinical investigators, and regulatory affairs professionals to capture operational realities and strategic intent. Interview findings were triangulated with process descriptions and technology specifications from equipment and reagent suppliers to validate assumptions about scalability, comparability, and supply chain dependencies. Where applicable, anonymized case studies of recent process transfers and scale-up efforts informed practical guidance on risk mitigation and resource allocation.

Analytic rigor was maintained through cross-validation of claims, assessment of methodological biases, and explicit acknowledgement of data limitations. The study emphasizes reproducible methods and transparent assumptions, and it identifies areas where further primary data collection would strengthen decision-making. This methodology balances depth of insight with the need for actionable recommendations targeted to executives and technical leaders.

Concluding synthesis on how technological readiness, operational resilience, and regulatory alignment will determine which allogeneic programs achieve sustained clinical and commercial impact

In conclusion, the allogeneic cell therapy field stands at an inflection point where technological maturation, supply chain strategy, and regulatory adaptation converge to determine which programs will achieve durable clinical and commercial success. Off-the-shelf products can unlock broader patient access and streamlined delivery models, but realizing that potential requires deliberate alignment across scientific design, manufacturing scalability, and payer engagement.

Operational resilience-evidenced by diversified sourcing, robust analytics, and flexible manufacturing-will distinguish leaders from laggards. Meanwhile, regulatory clarity around gene editing, potency assays, and post-market surveillance will shape development priorities and evidence generation strategies. Finally, regional footprint decisions and responses to trade policy shifts will materially affect cost structures and access pathways. The organizations that integrate these dimensions into coherent development programs will be best positioned to translate clinical promise into sustained patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allogeneic Cell Therapy Market, by Product Type

  • 8.1. CAR-T Therapy
    • 8.1.1. Gene Edited
    • 8.1.2. Non Gene Edited
  • 8.2. Dendritic Cell Therapy
    • 8.2.1. Immature Dendritic
    • 8.2.2. Mature Dendritic
  • 8.3. NK Cell Therapy
    • 8.3.1. Engineered
    • 8.3.2. Unmodified
  • 8.4. Stem Cell Therapy
    • 8.4.1. Hematopoietic
    • 8.4.2. Mesenchymal

9. Allogeneic Cell Therapy Market, by Manufacturing Technology

  • 9.1. 2D Culture Systems
    • 9.1.1. Layered Flasks
    • 9.1.2. Roller Bottles
  • 9.2. 3D Spheroid Culture
    • 9.2.1. Scaffold Based
    • 9.2.2. Scaffold Free
  • 9.3. Bioreactor Systems
    • 9.3.1. Multi Use
    • 9.3.2. Single Use
  • 9.4. Microcarrier Based Systems
    • 9.4.1. Fixed Bed
    • 9.4.2. Stirred Tank

10. Allogeneic Cell Therapy Market, by Indication

  • 10.1. Autoimmune Disorders
    • 10.1.1. Lupus
    • 10.1.2. Multiple Sclerosis
    • 10.1.3. Rheumatoid Arthritis
  • 10.2. Cardiovascular Diseases
    • 10.2.1. Myocardial Infarction
    • 10.2.2. Peripheral Artery Disease
    • 10.2.3. Stroke
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial Infections
    • 10.3.2. Viral Infections
  • 10.4. Neurological Disorders
    • 10.4.1. Alzheimers
    • 10.4.2. Parkinsons
    • 10.4.3. Spinal Cord Injury
  • 10.5. Oncology
    • 10.5.1. Hematological Malignancies
    • 10.5.2. Solid Tumors

11. Allogeneic Cell Therapy Market, by Cell Source

  • 11.1. Adipose Tissue
  • 11.2. Bone Marrow
  • 11.3. Peripheral Blood
  • 11.4. Umbilical Cord

12. Allogeneic Cell Therapy Market, by End User

  • 12.1. Contract Research Organization
  • 12.2. Hospital
  • 12.3. Research Institute
  • 12.4. Specialty Clinic

13. Allogeneic Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Allogeneic Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Allogeneic Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Allogeneic Cell Therapy Market

17. China Allogeneic Cell Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abeona Therapeutics Inc.
  • 18.6. AlloSource
  • 18.7. Anterogen.Co., Ltd.
  • 18.8. Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • 18.9. Athersys Inc.
  • 18.10. Biorestorative Therapies Inc.
  • 18.11. Biosolution Co., Ltd.
  • 18.12. Bloodworks Northwest
  • 18.13. Brainstorm Cell Limited
  • 18.14. Caribou Biosciences
  • 18.15. Fate Therapeutics
  • 18.16. Gamida Cell
  • 18.17. Hope Biosciences
  • 18.18. JCR Pharmaceuticals Co., Ltd.
  • 18.19. Mallinckrodt Pharmaceuticals
  • 18.20. MEDIPOST Co., Ltd.
  • 18.21. Mesoblast Ltd.
  • 18.22. NuVasive Inc. by Globus Medical
  • 18.23. RTI Surgical
  • 18.24. Smith+Nephew PLC
  • 18.25. Stempeutics Research Pvt. Ltd.
  • 18.26. Sumitomo Pharma Co., Ltd.
  • 18.27. Takeda Pharmaceutical Company Limited
  • 18.28. Tego Science Inc.
  • 18.29. ViaCyte Inc. by Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ENGINEERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ENGINEERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ENGINEERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UNMODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UNMODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UNMODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ALLOGENEIC CELL THER